Nicotine therapeutic benefits: Difference between revisions

(3 intermediate revisions by the same user not shown)

Line 901:

**Citation: Wiersinga, W. M. (2013). Smoking and thyroid. Clinical Endocrinology, 79(2), 145–151. doi:10.1111/cen.12222

***Acknowledgement: None stated

='''HIV (human immunodeficiency virus)'''=

===2025: [https://www.sciencedirect.com/science/article/abs/pii/S0149763425003495 Nicotine and neurocognition in HIV: Translational challenges and therapeutic potential]===

*"Approximately half of people with HIV (PWH) experience neurocognitive impairment (NCI), despite antiretroviral therapies that have turned what was formerly a death sentence to a chronic illness. No targeted treatments exist for HIV-associated NCI, impacting long-term quality of life. Smoking rates in PWH are nearly double those of the general population, and with evidence for pro-cognitive effects of nicotine, this may reflect self-medication. However, clinical studies yield inconsistent findings-some showing benefits, others reporting harm-likely due to variability in nicotine exposure methods, cognitive testing paradigms, withdrawal states, and confounding comorbidities. In contrast, animal studies offer a more controlled framework to isolate the effects of nicotine. Preclinical models suggest that nicotine may mitigate HIV-associated cognitive deficits by acting on α7 nicotinic acetylcholine receptors (nAChRs), leading to reduced neuroinflammation. These findings highlight the therapeutic potential of targeting nAChRs, though mechanisms remain incompletely understood..."

**Citation: Jha NA, Ayoub SM, Brody AL, Young JW. Nicotine and neurocognition in HIV: Translational challenges and therapeutic potential. Neurosci Biobehav Rev. 2025 Aug 23;177:106348. doi: 10.1016/j.neubiorev.2025.106348. Epub ahead of print. PMID: 40854454.

***Acknowledgement: This work was supported by the National Institutes of Health [grant numbers: R01MH134175 (JWY), R01MH128869 (JWY), R01DA051295 (JWY)]...

===2021: [https://pmc.ncbi.nlm.nih.gov/articles/PMC11334575/ Meta-Analysis on Nicotine's Modulation of HIV-Associated Dementia]===

*However, alternative pathways with more holistic representations of molecular relationships revealed the potential of nicotine as a neuroprotective treatment. It was found that concurrent with nicotine treatment the individual inactivation of several of the intermediary molecules in the holistic pathways caused the downregulation of the HAD pathology molecules. These findings reveal that nicotine may have therapeutic properties for HAD when given alongside specific inhibitory drugs for one or more of the identified intermediary molecules.

**Citation: Krishnan, V., Vigorito, M., Kota, N.K. et al. Meta-Analysis on Nicotine's Modulation of HIV-Associated Dementia. J Neuroimmune Pharmacol 17, 487–502 (2022). https://doi.org/10.1007/s11481-021-10027-2

***Acknowledgement: This study was partially supported by National Institute of Health grants DA43448 and DA046258 to SLC.

='''Huntington’s Disease'''=

Line 1,092:

Line 1,104:

*Citation: Lewis AS, van Schalkwyk GI, Lopez MO, Volkmar FR, Picciotto MR, Sukhodolsky DG. An Exploratory Trial of Transdermal Nicotine for Aggression and Irritability in Adults with Autism Spectrum Disorder. J Autism Dev Disord. 2018 Aug;48(8):2748-2757. doi: 10.1007/s10803-018-3536-7. PMID: 29536216; PMCID: PMC6394231.

*Acknowledgements: This work was supported by Autism Speaks grant #9699 (ASL), National Institutes of Health grants R01DA14241 and R01MH077681 (MRP), R25MH071584, T32MH019961, and T32MH14276 (ASL), and the Child Study Center Associates and the AACAP Pilot Award for General Psychiatry Residents (GIvS).

*Keywords: Nicotine; nicotinic acetylcholine receptor; autism spectrum disorder; aggression; irritability; adult; sleep

<br>

Line 1,189:

Line 1,200:

===1996 [https://psycnet.apa.org/record/1996-00468-019 Depression and smoking cessation: Characteristics of depressed smokers and effects of nicotine replacement.]===

*

*Depressed smokers relapsed significantly earlier than the nondepressed. Nicotine gum was significantly more effective than placebo gum among all smokers. The benefits of nicotine gum were particularly apparent among the depressed. Only 12.5% of depressed smokers quit successfully with placebo gum for 3 months, whereas 29.5% quit with nicotine gum. Depressed smokers reported more stress, less coping resources, more physical and psychological symptoms, and more frequent smoking in the presence of negative affect than did the nondepressed.

*[https://sci-hub.st/10.1037/0022-006X.64.4.791 PDF Version]

*Citation:

**Citation: Kinnunen, T., Doherty, K., Militello, F. S., & Garvey, A. J. (1996). Depression and smoking cessation: Characteristics of depressed smokers and effects of nicotine replacement. Journal of Consulting and Clinical Psychology, 64(4), 791–798. https://doi.org/10.1037/0022-006X.64.4.791

===1995 [https://pubmed.ncbi.nlm.nih.gov/8619011/ Effects of transderman nicotine on mood and sleep in nonsmoking major depressed patients]===

Line 1,867:

Line 1,878:

===2021: [https://link.springer.com/article/10.1007/s12640-021-00375-5 Novel Pharmacotherapies in Parkinson’s Disease]===

*[https://sci-hub.st/10.1007/s12640-021-00375-5 PDF Full paper]

===2001: [https://today.duke.edu/2001/08/mm_medicaluses.html Medical Uses for Nicotine]===

@@ Line 901: / Line 901: @@
 **Citation: Wiersinga, W. M. (2013). Smoking and thyroid. Clinical Endocrinology, 79(2), 145–151. doi:10.1111/cen.12222
 ***Acknowledgement: None stated
+='''HIV (human immunodeficiency virus)'''=
+===2025: [https://www.sciencedirect.com/science/article/abs/pii/S0149763425003495 Nicotine and neurocognition in HIV: Translational challenges and therapeutic potential]===
+*"Approximately half of people with HIV (PWH) experience neurocognitive impairment (NCI), despite antiretroviral therapies that have turned what was formerly a death sentence to a chronic illness. No targeted treatments exist for HIV-associated NCI, impacting long-term quality of life. Smoking rates in PWH are nearly double those of the general population, and with evidence for pro-cognitive effects of nicotine, this may reflect self-medication. However, clinical studies yield inconsistent findings-some showing benefits, others reporting harm-likely due to variability in nicotine exposure methods, cognitive testing paradigms, withdrawal states, and confounding comorbidities. In contrast, animal studies offer a more controlled framework to isolate the effects of nicotine. Preclinical models suggest that nicotine may mitigate HIV-associated cognitive deficits by acting on α7 nicotinic acetylcholine receptors (nAChRs), leading to reduced neuroinflammation. These findings highlight the therapeutic potential of targeting nAChRs, though mechanisms remain incompletely understood..."
+**Citation: Jha NA, Ayoub SM, Brody AL, Young JW. Nicotine and neurocognition in HIV: Translational challenges and therapeutic potential. Neurosci Biobehav Rev. 2025 Aug 23;177:106348. doi: 10.1016/j.neubiorev.2025.106348. Epub ahead of print. PMID: 40854454.
+***Acknowledgement: This work was supported by the National Institutes of Health [grant numbers: R01MH134175 (JWY), R01MH128869 (JWY), R01DA051295 (JWY)]...
+===2021: [https://pmc.ncbi.nlm.nih.gov/articles/PMC11334575/ Meta-Analysis on Nicotine's Modulation of HIV-Associated Dementia]===
+*However, alternative pathways with more holistic representations of molecular relationships revealed the potential of nicotine as a neuroprotective treatment. It was found that concurrent with nicotine treatment the individual inactivation of several of the intermediary molecules in the holistic pathways caused the downregulation of the HAD pathology molecules. These findings reveal that nicotine may have therapeutic properties for HAD when given alongside specific inhibitory drugs for one or more of the identified intermediary molecules.
+**Citation: Krishnan, V., Vigorito, M., Kota, N.K. et al. Meta-Analysis on Nicotine's Modulation of HIV-Associated Dementia. J Neuroimmune Pharmacol 17, 487–502 (2022). https://doi.org/10.1007/s11481-021-10027-2
+***Acknowledgement: This study was partially supported by National Institute of Health grants DA43448 and DA046258 to SLC.
 ='''Huntington’s Disease'''=
@@ Line 1,092: / Line 1,104: @@
 *Citation: Lewis AS, van Schalkwyk GI, Lopez MO, Volkmar FR, Picciotto MR, Sukhodolsky DG. An Exploratory Trial of Transdermal Nicotine for Aggression and Irritability in Adults with Autism Spectrum Disorder. J Autism Dev Disord. 2018 Aug;48(8):2748-2757. doi: 10.1007/s10803-018-3536-7. PMID: 29536216; PMCID: PMC6394231.
 *Acknowledgements: This work was supported by Autism Speaks grant #9699 (ASL), National Institutes of Health grants R01DA14241 and R01MH077681 (MRP), R25MH071584, T32MH019961, and T32MH14276 (ASL), and the Child Study Center Associates and the AACAP Pilot Award for General Psychiatry Residents (GIvS).
-*Keywords: Nicotine; nicotinic acetylcholine receptor; autism spectrum disorder; aggression; irritability; adult; sleep
 <br>
@@ Line 1,189: / Line 1,200: @@
 ===1996 [https://psycnet.apa.org/record/1996-00468-019 Depression and smoking cessation: Characteristics of depressed smokers and effects of nicotine replacement.]===
-*
+*Depressed smokers relapsed significantly earlier than the nondepressed. Nicotine gum was significantly more effective than placebo gum among all smokers. The benefits of nicotine gum were particularly apparent among the depressed. Only 12.5% of depressed smokers quit successfully with placebo gum for 3 months, whereas 29.5% quit with nicotine gum. Depressed smokers reported more stress, less coping resources, more physical and psychological symptoms, and more frequent smoking in the presence of negative affect than did the nondepressed.
 *[https://sci-hub.st/10.1037/0022-006X.64.4.791 PDF Version]
-*Citation:
+**Citation: Kinnunen, T., Doherty, K., Militello, F. S., & Garvey, A. J. (1996). Depression and smoking cessation: Characteristics of depressed smokers and effects of nicotine replacement. Journal of Consulting and Clinical Psychology, 64(4), 791–798. https://doi.org/10.1037/0022-006X.64.4.791
 ===1995 [https://pubmed.ncbi.nlm.nih.gov/8619011/ Effects of transderman nicotine on mood and sleep in nonsmoking major depressed patients]===
@@ Line 1,867: / Line 1,878: @@
 ===2021: [https://link.springer.com/article/10.1007/s12640-021-00375-5 Novel Pharmacotherapies in Parkinson’s Disease]===
+*[https://sci-hub.st/10.1007/s12640-021-00375-5 PDF Full paper]
 ===2001: [https://today.duke.edu/2001/08/mm_medicaluses.html Medical Uses for Nicotine]===